Cutting-edge technologies to accelerate, validate, and democratize preclinical oncology. 

Every Tumor, Every Stage

Using our proprietary, tunable, and tissue-specific bioinks we are developing a library of 3D tumor models that replicate key aspects associated with cancer growth and metastasis.

3D Bioprinted Tumoroids

Using our proprietary bioactive hydrogels, we construct tumor organoids: 3D cellular structures made from cancerous cells. These structures allow for more natural cell-to-cell signaling and growth than can be achieved in traditional 2D cell cultures or in animal xenograft models.

Unveiling the Barriers: Challenges in Preclinical Oncology

Current methods of preclinical testing tail to capture the chemical and physical factors that influence cancer growth and treatment. Despite each late-stage clinical trial costing billions of dollars per drug, animal models continue to be widespread because there simply is no alternative. That is, until now. 

Image of a purple liquid being pipetted into one of many small test tubes, by Lois Reed on Unsplash

Poor Translation

Only 3% of cancer therapeutics that start phase I clinical trials will actually make it to market1. This leads to billions of dollar wasted on clinical trials2

black and white image of a stethoscope on a white cloth, by Hush Naidoo Jade Photography on Unsplash

Diversity Gap

The medical field has historically failed to account for patient diversity corresponding to sex, race, age, and co-morbid factors

Image of a brown rodent resting on a rubber mat, by Ranjith Jaya on Unsplash

Animal Welfare

Animal testing presents an ethical dilemma, and animal model data does not necessarily translate into humans

Preclinical Oncology: Validated, Accelerated, Democratized

Validated: Clinical Results Replicated

To demonstrate the promise of our platform we will validate our tumor models against previous clinical results using a retroactive, blinded study where we will show our ability to replicate clinical data within our system - stepping away from guesswork and towards reproducible successes. 

Accelerated: The Tumor Microenvironment

The microenvironment is what surrounds and supports our cells, and helps provide structure to the various tissues that make up our bodies. The physical and chemical aspects and components of a tumor's microenvironment are critical for directing how the tumor grows and spreads in the body. By replicating the tumor microenvironment, TissueTinker provides a more realistic representation of tumors as they appear in the body.

representative image of the tumor microenvironment. A cell and an extracellular vesicle are encased in the extracellular matrix
Image of the hands of five people of different ethnicities and sexes lined up together on a wooden table, by Clay Banks on Unsplash

Democratized: Preclinical Testing For All

Our models are agnostic of the original cell source, and can be readily used with both patient cells and immortalized cell lines. This allows us to further democratize healthcare by testing new therapeutics on cells from patients of a variety of different backgrounds and health states.

Steps to Success

Image of an automatic pipetting machine dispensing liquid into sample tubes, by the National Cancer Institute on Unsplash

High-Throughput Analysis

Our platform supports tumors that fit within a 96-well plate, enabling rapid and reproducible high-throughput analysis. We are developing curated sample panels for nanoparticles, mAbs, and small molecule drugs.

Three-Dimensional Landscape of Genome. HIPMap (high-throughput imaging position mapping) accurately determines the position of a gene in the three-dimensional (3D) space of the cell nucleus. In this illustration, images of genes (red, green, and blue spots within the nuclei of HeLa cells) are artificially superimposed on images of multi-well plates. Creator: Tom Misteli, Sigal Shachar, Murali Palangat.

Library Expansion

By engineering tissue-specific bioinks, we will expand our library by creating even more specialized tumor models: Every tumor, every stage.

Human colorectal cancer cells treated with a topoisomerase inhibitor and an inhibitor of the protein kinase ATR (ataxia telangiectasia and Rad3 related), a drug combination under study as a cancer therapy. Cell nuclei are stained blue; the chromosomal protein histone gamma-H2AX marks DNA damage in red and foci of DNA replication in green. Created by Yves Pommier, Rozenn Josse, 2014

Rare Cancers

Using our model library, we will develop new therapeutics for rare and underserved cancers by leveraging our backgrounds in mRNA technology, nanotechnology, and biotherapeutic formulation.

Interested in learning more?

Click the button below or email us at info@tissuetinker.com

LinkedIn

 Follow us on LinkedIn for updates